TATTOOSTAR EFFECT COMBO

K131757 · Asclepion Laser Technologies GmbH · GEX · Jul 17, 2014 · General, Plastic Surgery

Device Facts

• Record ID: K131757
• Device Name: TATTOOSTAR EFFECT COMBO
• Applicant: Asclepion Laser Technologies GmbH
• Product Code: GEX · General, Plastic Surgery
• Decision Date: Jul 17, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The TattooStar Effect Combo is indicated for incision, excision, ablation and vaporization of soft tissue in general dermatology and the removal of tattoos, pigmented lesions, vascular lesions and unwanted hair and skin resurfacing procedures.

Device Story

TattooStar Effect Combo is a multi-wavelength laser system combining Nd:YAG (1064nm, 532nm, optional 585nm dye) and Ruby (694nm) lasers. Both operate as pulsed q-switched lasers; Nd:YAG also supports free-running mode. Device delivers laser energy via articulated mirror arm to target tissue. Used in clinical dermatology settings by physicians for soft tissue procedures, tattoo removal, pigmented/vascular lesion treatment, hair removal, and skin resurfacing. Output is controlled laser radiation; provider selects wavelength and parameters based on clinical indication. Device enables precise tissue ablation or pigment destruction, facilitating dermatological treatment and aesthetic improvement.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on technological characteristics and performance parameters identical to the predicate devices.

Technological Characteristics

Combination Nd:YAG and Ruby laser system. Nd:YAG wavelengths: 1064nm, 532nm, 585nm (via dye handpiece). Ruby wavelength: 694nm. Delivery via articulated mirror arm. Q-switched pulse durations: 8ns (Nd:YAG), 40ns (Ruby). Nd:YAG free-running mode: 300µs. Repetition rates up to 10Hz (Nd:YAG) and 2Hz (Ruby). Fluence up to 37 J/cm² (free-running) and 25 J/cm² (q-switched).

Indications for Use

Indicated for incision, ablation, and vaporization of soft tissue in general dermatology, removal of tattoos, pigmented lesions, and skin resurfacing. Specific applications depend on wavelength: 1064nm (black/blue tattoos, skin resurfacing), 532nm (pigmented lesions, red tattoos), 585nm (sky blue tattoos), and 694nm (pigmented lesions, black/blue/green tattoos).

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• TattooStar Effect Y (K112669)
• TattooStar R (K060787)

Submission Summary (Full Text)

{0}------------------------------------------------

## 510(k) SUMMARY ASCLEPION LASÈR TECHNOLOGIES GmbH TattooStar Effect Combo

JUL 17 2014 KI31757

This 510(k) summary of safety and effectiveness for the Asclepion Laser Technologies GmbH TattooStar Effect Combo is submitted in accordance with the requirements of 21 CFR 807.92 and follows Office of Device Evaluation Guidance concerning the organization and content of a 510(k) summary.

| Applicant: | ASCLEPION LASER TECHNOLOGIES GmbH<br>Bruesseler Str. 10<br>07747 Jena, Germany | |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Contact Person: | Mrs. Antje Katzer<br>Product Manager and<br>International Regulatory Affairs Manager | |
| Phone:<br>Fax:<br>e-mail: | [phone]<br>[phone]<br>[e-mail] | |
| Preparation Date: | July 15, 2014 | |
| Device Name: | TattooStar Effect Combo | |
| Common Name: | q-switch laser | |
| Classification Name: | Laser surgical instrument for use in general and plastic surgery<br>and in dermatology<br>79-GEX<br>21 CFR 878.4810 | |
| Equivalent Devices: | TattooStar Effect Y<br>TattooStar R | K112669<br>K060787 |
| Device Description: | The TattooStar Effect Combo is a combination of a Nd:YAG laser<br>and a Ruby laser. Both lasers are pulsed q-switched lasers, the<br>Nd:YAG can optionally emit millisecond pulses in the Free-<br>running mode. The Nd:YAG laser emits wavelengths of 1064nm<br>and 532nm. The beam can be converted to 585nm by means of<br>an optional dye handpiece. The Ruby laser emits 694 nm<br>radiation. | |

{1}------------------------------------------------

The TattooStar Effect Combo is indicated for incision, Intended Use: excision, ablation and vaporization of soft tissue in general dermatology and the removal of tattoos, pigmented lesions, vascular lesions and unwanted hair and skin resurfacing procedures.

| | Proposed Modified Device | Un-Modified Predicate Device |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Name | TattooStar Effect Combo<br>Modul: R (Ruby laser) | TattooStar R<br>K060787 |
| Indications | Incision, excision, vaporization<br>and ablation of soft tissue, the<br>removal of tattoos and benign<br>pigmented lesions | Cutting, vaporization and<br>ablation of soft tissue, the<br>removal of tattoos and of benign<br>pigmented lesions |
| | There are the same treatment recommendations for both systems: | |
| | 694nm: Removal of pigmented lesions: 3 J/cm², 4-5.5 mm, 0.5-2 Hz, 40 ns<br>Removal of black, blue and green tattoo: 2-3 J/cm², 4-5.5 mm, 0.5-2 Hz, 40 ns | |
| Device Type | Ruby | Ruby |
| Delivery | Articulated mirror arm | Articulated mirror arm |
| Wavelength | 694 nm | 694 nm |
| Max. Energy per<br>Pulse | 1,15 J | 1,2 J |
| Max. Fluence on<br>skin | 25 J/cm² | 20 J/cm² |
| Pulse Duration<br>q-switch | 40 ns | 40 ns |
| Repetition Rate | Up to 2 Hz | Up to 2 Hz |
| Spot Sizes | 2 – 7 mm | 2,5 - 6 mm |
| | Proposed Modified Device | Un-Modified Predicate Device |
| Name | TattooStar Effect Combo<br>Modul: Y (Nd:YAG laser) | TattooStar Effect Y<br>Modul: Y (Nd:YAG laser)<br>K112669 |
| Indications | Incision, excision, vaporization and<br>ablation of soft tissue, the removal of<br>tattoos, pigmented lesions, vascular<br>lesions and hair and skin resurfacing<br>procedures | Incision, excision, vaporization<br>and ablation of soft tissue, the<br>removal of tattoos, pigmented<br>lesions, vascular lesions and hair<br>and skin resurfacing procedures |
| | There are the same treatment recommendations for both systems: | |
| | 1064 nm: Removal of black and blue tattoo color:<br>3-3.5 J/cm², 2-4 mm, 1-10 Hz, 8 ns | |
| | Skin resurfacing: | 1.5-2.5 J/cm², 5.5 mm,<br>10 Hz, 0.3 ms<br>1.5 J/cm²,<br>7 mm,<br>2-5 Hz, 8 ns |
| | 532 nm: Removal of pigmented lesions<br>(including but not limited to lentigo benigna,<br>hyperpigmented burn and boil scar, naevus Ota / Ito,<br>freckles, Becker naevi, Café-au-lait spots):<br>2-2.5 J/cm²,<br>4 mm,<br>1-5 Hz,<br>8 ns | |
| | Removal of red tattoo color: | 2 J/cm²,<br>4 mm,<br>1-5 Hz,<br>8 ns |
| | 585 nm: Removal of sky blue tattoo color: | 2-3 J/cm²,<br>2.5 mm,<br>1-5 Hz,<br>8 ns |
| Device Type | Nd :YAG | Nd :YAG |
| Delivery | Articulated mirror arm | Articulated mirror arm |
| Wavelength | 1064 / 532 / 585 nm | 1064 / 532 / 585 nm |
| Max.<br>Energy per<br>Pulse | 1064 nm: 0,8 J (q-switch mode)<br>1064 nm: 1,5 J (free running mode)<br>532 nm: 0,4 J (q-switch mode)<br>585 nm: 0,25 J (q-switch mode) | 1064 nm: 0,8 J (q-switch mode)<br>1064 nm: 1,5 J (free running mode)<br>532 nm: 0,4 J (q-switch mode)<br>585 nm: 0,25 J (q-switch mode) |
| Max.<br>Fluence on<br>skin | 20 J/cm² (q-switch mode)<br>37 J/cm² (free running mode) | 20 J/cm² (q-switch mode)<br>37 J/cm² (free running mode) |
| Pulse<br>Duration<br>q-switch | 8 ns (q-switch mode)<br>300 µs (free running mode) | 8 ns (q-switch mode)<br>300 µs (free running mode) |
| Repetition<br>Rate | Up to 10 Hz | Up to 10 Hz |
| Spot Sizes | 2 – 7 mm | 2 – 7 mm |

{2}------------------------------------------------

.

·

・

.

{3}------------------------------------------------

The TattooStar Effect Combo is substantially equivalent to Comparison to: the TattooStar Effect Y Laser system and to the TattooStar R with the same principles of operation, with the same parameters and with the same indications for use.

Nonclinical Performance Data: None

Clinical Performance Data: None

Conclusion: The TattooStar Effect Combo is another safe and effective device for the incision, excision, ablation and vaporization of soft tissue in general dermatology and the removal of tattoos, pigmented lesions, vascular lesions and unwanted hair and skin resurfacing procedures.

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle or bird-like symbol with three curved lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the symbol.

### DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Control - WO66-G609 Silver Spring, MD 20993-0002

July 17, 2014

Asclepion Laser Technologies GmbH Mr. Antje Katze Regulatory Affairs Manager Bruesseler Street 10 Jena, Germanv 07747

Re: K131757

Trade/Device Name: TattooStar Effect Combo Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: June 20, 2014 Received: June 24, 2014

Dear Mr. Katzer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you: however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

{5}------------------------------------------------

Page 2 - Mr. Antje Katze

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21

CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

## David Krause -S

Binita S. Ashar, M.D., M.B.A., F.A.C.S. for Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

#### 510(k) Number (if known) K131757

Device Name TattooStar Effect Combo

#### Indications for Use (Describe)

The TattooStar Effect Combo is indicated for incision, ablation and vaporization of soft tissue in general dermatology and the removal of tattoos, pigmented lesions and skin resurfacing procedures. Depending on the wavelength selected, the indications are as follows:

| Wavelength | Indication | Recommended Parameters for the Beginning |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| 1064 nm: | Removal of black and blue tattoo color | 3-3.5 J/cm^2, 2-4 mm, 1-10Hz, 8 ns |
| | Skin resurfacing | 1.5-2.5 J/cm^2, 5.5 mm, 10 Hz, 0.3 ms<br>1.5 J/cm^2, 7 mm, 2-5 Hz, 8 ns |
| 532 nm: | Removal of pigmented lesions<br>(including but not limited to lentigo benigna,<br>hyperpigmented bum and boil scar,<br>naevus Ota / Ito, freckles, Becker naevi,<br>Cafe-au-lait spots) | 2-2.5 J/cm^2 4mm, 1-5Hz, 8 ns |
| | Removal of red tattoo color | 2 J/cm^2, 4mm, 1-5Hz, 8ns |
| 585 nm: | Removal of sky blue tattoo color | 2-3 J/cm^2, 2.5mm, 1-5Hz, 8 ns |
| 694nm: | Removal of pigmented lesions | 3 J/cm^2, 4-5.5 mm, 0.5-2 Hz, 40 ns |
| | Removal of black, blue and green<br>tattoo color | 2-3 J/cm^2, 4-5.5 mm, 0.5-2 Hz, 40 ns |
| | Type of Use (Select one or both, as applicable) | |
| | Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |

## PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

# Neil R Ogden -S 2014.07.17 11:18:23 -04'00' > < ---

{7}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995. 'DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.'

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."